A choroidal neovascular membrane (CNVM) is an abnormal layer of blood vessels that grows from the choroid, the vascular tissue beneath the retina, up through the barrier known as Bruch’s membrane and into the space under or within the retina itself. These new vessels are fragile, leaky, and prone to bleeding, which is why they can cause rapid and sometimes devastating loss of central vision. The condition is most commonly linked to age-related macular degeneration but can also appear in younger people for entirely different reasons, and modern treatments have fundamentally changed what used to be a near-certain path toward blindness.
How a Choroidal Neovascular Membrane Forms
The retina sits on top of a thin, layered sheet called Bruch’s membrane, which acts as a filter and structural barrier between the retina’s support cells and the blood-vessel-rich choroid underneath. When Bruch’s membrane weakens or develops breaks, the blood vessels below can push through into territory they were never meant to occupy. High-resolution imaging studies define these breaks as definite interruptions or focal defects in the membrane that are associated with changes in the underlying blood vessels, sometimes with visible vascular growth through the gap.1Investigative Ophthalmology & Visual Science. In Vivo Characterization of Bruch’s Membrane Breaks in Neovascular Age-Related Macular Degeneration Using High-Resolution Optical Coherence Tomography
The key chemical driver of this process is vascular endothelial growth factor, usually shortened to VEGF. VEGF is a signaling protein that tells the body to build new blood vessels, a useful function in wound healing but destructive in the eye. Research in animal models has shown that even a temporary spike of VEGF production by the retinal pigment epithelium is enough to trigger the growth of new vessels from the choroid, through Bruch’s membrane, and into the subretinal space, ultimately forming a neovascular membrane and killing overlying photoreceptor cells.2PubMed Central. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization Understanding VEGF as the central villain is what led to the treatments that now exist, and it also explains why ongoing blockade of this protein is the backbone of modern therapy.
Conditions That Cause CNVM
Age-related macular degeneration is the most common cause by a wide margin. The neovascular or “wet” form of AMD is a progressive retinal degenerative disease mainly affecting older adults, and it is defined by the growth of choroidal neovascularization in the macula.3PubMed Central. Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy But AMD is far from the only pathway. In younger patients, a choroidal neovascular membrane is often the result of pathologic myopia (severe nearsightedness), ocular histoplasmosis syndrome, angioid streaks, or idiopathic causes where no clear underlying disease is found.4PubMed. Vision loss in younger patients: a review of choroidal neovascularization
Pathologic myopia deserves special attention because it is the leading non-AMD cause of CNVM. In highly myopic eyes, the eyeball is elongated, which stretches and thins Bruch’s membrane and the choroid. A systematic review and meta-analysis found that highly myopic eyes with CNVM were nearly three times more likely to have lacquer cracks (tiny fissures in Bruch’s membrane) and over three times more likely to have patchy areas of chorioretinal atrophy compared with highly myopic eyes without CNVM. The choroid was also significantly thinner in affected eyes, and VEGF levels in the fluid inside the eye were considerably higher.5Survey of Ophthalmology. Pathogenesis of myopic choroidal neovascularization: A systematic review and meta-analysis This matters practically because myopic CNVM tends to show up decades earlier than AMD-related CNVM and can affect people in their twenties and thirties.
Other molecular factors beyond VEGF are also involved. Researchers have identified a protein called EFEMP1 (fibulin-3) that is elevated in the retinal-choroid tissues of eyes with AMD, with a more significant increase in wet AMD than dry AMD. EFEMP1 appears to drive new vessel formation partly by upregulating VEGF itself, suggesting a chain of molecular events rather than a single switch.6PubMed Central. EFEMP1 Overexpression Contributes to Neovascularization in Age-Related Macular Degeneration
Risk Factors You Can and Cannot Control
Beyond the underlying eye conditions, a cluster of cardiovascular risk factors sharply increases the odds of developing a neovascular membrane. A study that adjusted for multiple confounders found that a history of cardiovascular disease was the single strongest risk factor, raising the odds of neovascular AMD roughly sevenfold. Cigarette smoking nearly quadrupled the risk, and being in the highest quartile for body mass index or serum cholesterol increased it roughly three- to fivefold. Stage 2 hypertension tripled the risk.7Ophthalmology. Cardiovascular Disease and Hypertension Are Strong Risk Factors for Choroidal Neovascularization
The overlap between heart-health risk factors and eye-health risk factors is not a coincidence. The choroid is one of the most blood-vessel-dense tissues in the body, and anything that damages blood vessels systemically tends to damage the choroid as well. This is actually a useful thing to know, because it means the same lifestyle changes that reduce heart disease risk, such as quitting smoking, managing blood pressure, and maintaining a healthy weight, also reduce the likelihood that a neovascular membrane will form or progress.
What CNVM Feels Like
The hallmark symptom is a sudden or rapid change in the quality of central vision. Most people first notice that straight lines, like door frames or text on a page, look bent or wavy. This distortion, called metamorphopsia, happens because the leaking fluid and growing membrane physically distort the retinal layers responsible for fine detail. A blurry or dark spot in the center of your visual field can follow, making it hard to read, recognize faces, or drive.
In some cases the membrane bleeds into the subretinal space, producing a sudden, dramatic vision loss. Subretinal hemorrhage is especially common in neovascular AMD but also occurs with ocular histoplasmosis and high myopia. The blood itself is toxic to photoreceptors: released compounds, mechanical shear, and the barrier the blood creates between photoreceptors and their nutrient supply all contribute to cell death and permanent visual loss if the hemorrhage is not addressed quickly.
Peripheral vision is typically unaffected because the membrane grows at or near the macula, the small area responsible for sharp central sight. This means you can still navigate a room, but the tasks that depend on fine acuity, reading a book, threading a needle, seeing the dashboard clearly, become progressively more difficult.
How CNVM Is Diagnosed
The gold standard for decades was fluorescein angiography (FA), in which a yellow dye is injected into a vein and photographs are taken as it flows through the retinal and choroidal blood vessels. Classic CNVM shows up as a well-defined bright area in the early frames that intensifies and spreads in later frames, while occult (hidden) CNVM produces a more subtle, late-onset leakage pattern.8Scientific Reports. Angiographic Subtypes of Neovascular Age-related Macular Degeneration in Korean: A New Diagnostic Challenge The distinction between classic and occult subtypes matters because they can behave differently and may respond differently to treatment.
Optical coherence tomography angiography (OCT-A) has increasingly moved into clinical practice as a non-invasive alternative. It maps retinal and choroidal blood flow without any dye injection, which is both faster and free of the rare allergic reactions that fluorescein can trigger. In one clinical study, combined use of structural OCT with OCT-A achieved roughly 89% sensitivity and 87% specificity for detecting CNVM in treatment-naïve wet AMD patients.9PubMed Central. Optical coherence tomography angiography for identifying choroidal neovascular membranes: a masked study in clinical practice That is quite good, though not perfect. Another study comparing OCT-A directly to fluorescein angiography found overall sensitivity of about 71% and specificity of about 81%, but with a notable subtype split: OCT-A detected classic (type II) CNVM with 100% sensitivity while only catching occult (type I) CNVM about 47% of the time.10Eye. The use of optical coherence tomography angiography for detecting choroidal neovascularization, compared to standard multimodal imaging
The practical takeaway is that OCT-A works well as a frontline screening tool and for monitoring treatment response, but fluorescein angiography still has a role when the clinical picture is ambiguous, especially for occult membranes. Many retinal specialists now use both modalities together, leaning on each where it is strongest.
Anti-VEGF Injections as First-Line Treatment
The introduction of drugs that block VEGF transformed the treatment of CNVM from damage control into genuine vision preservation and, in many cases, vision improvement. These medications, which include ranibizumab, aflibercept, and bevacizumab, are injected directly into the vitreous cavity of the eye. The procedure sounds alarming but takes only a few minutes, with numbing drops making it tolerable.
Anti-VEGF therapy works across the full range of CNVM causes, not just AMD. In patients with CNVM caused by conditions other than AMD, such as myopia or inflammatory disease, intravitreal anti-VEGF injections produced significant reductions in central macular thickness that were sustained through 12 months.11PubMed Central. Results of Intravitreal Anti-VEGF Injection in Choroidal Neovascularization Caused by Pathologies Other Than Age-Related Macular Degeneration In a study of patients treated with ranibizumab specifically, mean visual acuity improved significantly within three months and macular thickness dropped from about 390 microns to about 264 microns.12PubMed Central. Electrophysiologic changes after intravitreal ranibizumab injection for the treatment of choroidal neovascular membrane (CNVM)
However, anti-VEGF therapy is not a one-and-done fix. Most patients need repeated injections over months to years, and the debate in clinical practice centers on how best to schedule those injections.
Scheduling Strategies for Ongoing Treatment
Three main approaches exist for timing anti-VEGF injections after the initial loading phase:
- Fixed dosing: injections given at set intervals (usually monthly or every two months) regardless of how the eye looks.
- Pro re nata (PRN): injections given only when monitoring shows signs of disease activity, such as fluid reaccumulation on OCT.
- Treat-and-extend (T&E): after stabilizing the eye, the interval between injections is gradually lengthened as long as the disease stays quiet, and shortened again if it flares.
A systematic review and meta-analysis comparing these strategies found that treat-and-extend dosing preserved vision similarly to fixed monthly dosing at one and two years but required significantly fewer injections, roughly one to two fewer at one year and about seven fewer over two years. Compared to PRN, treat-and-extend produced meaningfully better visual gains, on the order of four to six extra letters on a standard eye chart, though it required somewhat more injections.13Eye. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis14American Journal of Ophthalmology. The Treat-and-Extend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis
Treat-and-extend has become the most widely adopted strategy in many practices because it balances good visual outcomes with fewer clinic visits. PRN requires frequent monitoring appointments even when no injection is given, which can be just as burdensome for patients. That said, the right schedule depends on how your individual eye responds, and some people do fine with a PRN approach if they are closely monitored and disease recurrence is caught early.15PubMed Central. Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study
Photodynamic Therapy and When It Is Used
Before anti-VEGF drugs arrived, photodynamic therapy (PDT) with verteporfin was one of the few options that could slow vision loss. The treatment involves infusing a light-sensitive drug into the bloodstream, then shining a non-thermal laser onto the neovascular membrane. The laser activates the drug locally, generating reactive molecules that damage the abnormal blood vessel walls without burning the surrounding retina the way traditional laser photocoagulation does.
PDT has not disappeared from clinical practice. It remains effective for certain subtypes, particularly polypoidal choroidal vasculopathy (PCV), a variant of neovascular AMD in which balloon-like vascular lesions form beneath the retina. For PCV, combined PDT plus anti-VEGF is often more effective than anti-VEGF alone. PDT has also been used effectively for peripapillary CNVM (membranes near the optic nerve), as well as for CNVM caused by ocular histoplasmosis and pathologic myopia.16PubMed Central. Verteporfin Photodynamic Therapy for the Treatment of Chorioretinal Conditions: A Narrative Review
Anti-VEGF Resistance and What Happens When Treatment Stops Working
Not everyone responds to anti-VEGF therapy indefinitely. Some patients experience a diminished therapeutic effect over time, a phenomenon broadly referred to as anti-VEGF resistance. The terminology is still unsettled: some researchers distinguish “refractory” cases, where the eye never fully responds, from “recurrent” cases, where the disease initially responds and then flares despite continued treatment. No consensus definition exists for either term, which makes comparing studies frustratingly difficult.17PubMed Central. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
When one anti-VEGF drug stops working, a common clinical move is to switch to a different one. The drugs block VEGF in slightly different ways, and some patients who plateau on ranibizumab improve after switching to aflibercept, or vice versa. The emerging class of bispecific antibodies offers a fundamentally different approach to the resistance problem.
Newer Drugs That Target More Than VEGF Alone
Faricimab is the first bispecific antibody designed for injection into the eye. Instead of blocking only VEGF, it simultaneously blocks angiopoietin-2 (Ang-2), a separate signaling molecule that destabilizes blood vessels and promotes inflammation. Data pooled across six phase III trials suggest that this dual blockade does a better job of reducing markers of vascular instability than VEGF inhibition alone, including better control of neovascularization, less fluid leakage, and reduced signs of inflammation.18PubMed Central. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases The hope is that targeting both pathways at once leads to longer intervals between injections and better long-term disease control, a meaningful benefit for patients who have been receiving shots every month or two for years.19Investigative Ophthalmology & Visual Science. Dual angiopoietin-2 and VEGF-A inhibition with faricimab in neovascular age-related macular degeneration: phase 3 TENAYA and LUCERNE trial design
Further down the pipeline, gene therapy aims to eliminate the need for repeated injections entirely. In preclinical work, a single subretinal injection of an engineered viral vector carrying an anti-VEGF gene produced sustained suppression of neovascularization and leakage, with the therapeutic protein remaining concentrated in the retina and choroid and showing minimal spread to the rest of the body.20PubMed Central. Preclinical evaluation of AAV2 anti-VEGF gene therapy using scFv for choroidal neovascularization If gene therapy proves safe and durable in human trials, it could transform CNVM management from a years-long cycle of injections into a single procedure. That remains a big “if,” but the early data are encouraging.
Living With CNVM and Its Effects Beyond Vision
The impact of a choroidal neovascular membrane extends well beyond blurry eyesight. Central vision loss disrupts the ability to read, recognize faces, watch television, and perform fine manual tasks.21Survey of Ophthalmology. Quality of Life in Patients With Age-related Macular Degeneration: Impact of the Condition and Benefits of Treatment A multicountry study comparing people with neovascular AMD to controls found that patients reported roughly 45% worse vision-related functioning, about 30% more anxiety, and about 42% more depression symptoms. The practical consequences were equally stark: the fall rate was doubled, and the need for help with daily activities was four times higher.22Archives of Ophthalmology. Burden and Health Care Resource Utilization in Neovascular Age-Related Macular Degeneration: Findings of a Multicountry Study
Depression deserves specific mention. A review of quality-of-life research found that the rate of depression among people with macular degeneration is roughly double what is seen in community-dwelling older adults without the condition. The shock of diagnosis, combined with inadequate information and support, is a common experience, and some patients report suicidal thoughts. Functional decline, loss of hobbies, and eroded independence all feed into this, especially when other health problems are present.23PubMed Central. Quality of life in age-related macular degeneration: a review of the literature
If you or someone you know receives a CNVM diagnosis, the emotional fallout is worth taking as seriously as the medical treatment. Low-vision rehabilitation services, peer support groups, and mental health screening can make a genuine difference in maintaining quality of life while the eye itself is being treated.
How Treatment Has Evolved Over the Decades
Before the 1980s, there was essentially no treatment for CNVM, and the condition progressed to severe central blindness in most cases. The development of fluorescein angiography made it possible to see the extent of the membrane for the first time, which led to laser photocoagulation. The Macular Photocoagulation Study showed that direct laser treatment reduced vision loss compared with observation in select patients, but it worked by destroying the membrane along with the overlying retina, leaving a permanent blind spot. It was effective only for membranes that were not directly under the center of the macula.24American Journal of Ophthalmology. Choroidal neovascularization
Photodynamic therapy in the early 2000s represented a step forward because it could treat centrally located membranes without causing as much collateral damage. Then anti-VEGF drugs arrived and changed the prognosis entirely, not just slowing vision loss but reversing it in many patients. The trajectory from destructive laser to targeted molecular therapy over roughly three decades is one of the more striking success stories in ophthalmology, and the pace of development shows no sign of slowing down with bispecific antibodies and gene therapy now entering the picture.